NZ606364A - Oligonucleotide chelate complexes - Google Patents

Oligonucleotide chelate complexes

Info

Publication number
NZ606364A
NZ606364A NZ606364A NZ60636411A NZ606364A NZ 606364 A NZ606364 A NZ 606364A NZ 606364 A NZ606364 A NZ 606364A NZ 60636411 A NZ60636411 A NZ 60636411A NZ 606364 A NZ606364 A NZ 606364A
Authority
NZ
New Zealand
Prior art keywords
chelate complexes
oligonucleotide chelate
oligonucleotide
disclosed
pharmaceutically acceptable
Prior art date
Application number
NZ606364A
Other languages
English (en)
Inventor
Andrew Vaillant
Michel Bazinet
Original Assignee
Replicor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45594559&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ606364(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Replicor Inc filed Critical Replicor Inc
Publication of NZ606364A publication Critical patent/NZ606364A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
NZ606364A 2010-08-20 2011-08-18 Oligonucleotide chelate complexes NZ606364A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37525710P 2010-08-20 2010-08-20
PCT/CA2011/000956 WO2012021985A1 (en) 2010-08-20 2011-08-18 Oligonucleotide chelate complexes

Publications (1)

Publication Number Publication Date
NZ606364A true NZ606364A (en) 2014-12-24

Family

ID=45594559

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ606364A NZ606364A (en) 2010-08-20 2011-08-18 Oligonucleotide chelate complexes

Country Status (35)

Country Link
US (2) US8513211B2 (cg-RX-API-DMAC10.html)
EP (1) EP2605794B1 (cg-RX-API-DMAC10.html)
JP (1) JP5775581B2 (cg-RX-API-DMAC10.html)
KR (3) KR20150039873A (cg-RX-API-DMAC10.html)
CN (2) CN103768086B (cg-RX-API-DMAC10.html)
AU (1) AU2011291401B2 (cg-RX-API-DMAC10.html)
BR (1) BR112013003875B1 (cg-RX-API-DMAC10.html)
CA (2) CA2855690C (cg-RX-API-DMAC10.html)
CL (1) CL2013000445A1 (cg-RX-API-DMAC10.html)
CO (1) CO6670525A2 (cg-RX-API-DMAC10.html)
CR (1) CR20130069A (cg-RX-API-DMAC10.html)
CU (1) CU20130022A7 (cg-RX-API-DMAC10.html)
CY (1) CY1118207T1 (cg-RX-API-DMAC10.html)
DK (1) DK2605794T3 (cg-RX-API-DMAC10.html)
DO (1) DOP2013000041A (cg-RX-API-DMAC10.html)
EA (1) EA026660B1 (cg-RX-API-DMAC10.html)
EC (1) ECSP13012449A (cg-RX-API-DMAC10.html)
ES (1) ES2598556T3 (cg-RX-API-DMAC10.html)
GT (1) GT201300040A (cg-RX-API-DMAC10.html)
HR (1) HRP20161333T1 (cg-RX-API-DMAC10.html)
HU (1) HUE029521T2 (cg-RX-API-DMAC10.html)
IL (1) IL224237A (cg-RX-API-DMAC10.html)
LT (1) LT2605794T (cg-RX-API-DMAC10.html)
MX (1) MX340294B (cg-RX-API-DMAC10.html)
MY (1) MY160961A (cg-RX-API-DMAC10.html)
NZ (1) NZ606364A (cg-RX-API-DMAC10.html)
PH (1) PH12013500192B1 (cg-RX-API-DMAC10.html)
PL (1) PL2605794T3 (cg-RX-API-DMAC10.html)
PT (1) PT2605794T (cg-RX-API-DMAC10.html)
RS (1) RS55245B1 (cg-RX-API-DMAC10.html)
SG (1) SG187165A1 (cg-RX-API-DMAC10.html)
SI (1) SI2605794T1 (cg-RX-API-DMAC10.html)
SM (1) SMT201600370B (cg-RX-API-DMAC10.html)
WO (1) WO2012021985A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201300497B (cg-RX-API-DMAC10.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6047270B2 (ja) 2006-08-11 2016-12-21 バイオマリン テクノロジーズ ベー.フェー. Dnaリピートの不安定性に関連した遺伝的障害を治療するための方法及び手段
JP5646320B2 (ja) 2007-05-11 2014-12-24 アダイニクス, インコーポレイテッド 遺伝子発現と疼痛
NZ584793A (en) 2007-10-26 2012-05-25 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
CA2862628C (en) 2012-01-27 2021-08-24 Prosensa Technologies B.V. Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
PT2841578T (pt) 2012-04-23 2017-08-10 Biomarin Tech Bv Resumo
RU2668136C2 (ru) * 2012-05-10 2018-09-26 Эйдинкс, Инк. Композиции для доставки активных ингредиентов
HUE054875T2 (hu) * 2012-05-18 2021-10-28 Replicor Inc Oligonukleotid kelátkomplex-polipeptid készítmények és eljárások
AR091065A1 (es) * 2012-05-18 2014-12-30 Replicor Inc Una formulacion farmaceutica que comprende un quelato de oligonucleotidos antiviral para el tratamiento de una infeccion antiviral
CN104603271B (zh) * 2012-07-03 2019-07-19 马林生物科技有限公司 用于治疗肌肉萎缩症患者的寡核苷酸
CN104837501B (zh) 2012-08-30 2018-11-02 里普利科股份有限公司 治疗乙型肝炎及丁型肝炎感染的方法
KR20170029577A (ko) 2014-07-10 2017-03-15 레플리코르 인코포레이티드 B형 간염 및 d형 간염 바이러스 감염의 치료 방법
CN106661578B (zh) 2014-08-15 2020-08-04 埃迪恩克斯股份有限公司 用于疼痛治疗的寡核苷酸诱饵
WO2016030863A1 (en) 2014-08-29 2016-03-03 Glaxosmithkline Intellectual Property Development Limited Compounds and methods for treating viral infections
JP2018513127A (ja) 2015-04-23 2018-05-24 ジェロン・コーポレーションGeron Corporation 多価カチオン塩組成物を用いたポリヌクレオチド調製方法
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
US20200147124A1 (en) * 2018-11-08 2020-05-14 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
US20230250125A1 (en) 2020-04-01 2023-08-10 Janssen Biopharma, Inc. Nucleic acid polymers
WO2022109129A1 (en) * 2020-11-20 2022-05-27 Aligos Therapeutics, Inc. Conjugates of s-antigen transport inhibiting oligonucleotide polymers having enhanced liver targeting
TW202245809A (zh) 2020-12-18 2022-12-01 美商詹森藥物公司 用於治療b型肝炎病毒感染之組合療法
WO2022152869A1 (en) 2021-01-15 2022-07-21 Janssen Sciences Ireland Unlimited Company Use of oligonucleotides for individuals with hepatic impairment
JP2024521897A (ja) * 2021-06-02 2024-06-04 アタランタ セラピューティクス,インコーポレーテッド 治療用オリゴヌクレオチドを中枢神経系に送達するための組成物及び方法
CN117616121A (zh) 2021-07-09 2024-02-27 葛兰素史密斯克莱知识产权(第3号)有限公司 寡核苷酸用于具有肾脏损伤的个体的用途
EP4728073A1 (en) * 2023-06-16 2026-04-22 Ractigen Therapeutics Oligonucleotide formulation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2300938A1 (en) * 1997-08-20 1999-02-25 Somagenics, Inc. Antisense and antigene therapeutics with improved binding properties and methods for their use
JP3667047B2 (ja) * 1997-09-12 2005-07-06 キヤノン株式会社 人工核酸およびその製造方法、デオキシリボフラノース化合物、リボフラノース化合物およびこれらの製造方法
US6653467B1 (en) * 2000-04-26 2003-11-25 Jcr Pharmaceutical Co., Ltd. Medicament for treatment of Duchenne muscular dystrophy
JP4836366B2 (ja) * 2000-08-25 2011-12-14 雅文 松尾 デュシェンヌ型筋ジストロフィー治療剤
WO2005023829A1 (ja) * 2003-09-02 2005-03-17 Japan Science And Technology Agency 金属錯体型核酸
WO2005026188A1 (ja) * 2003-09-08 2005-03-24 Japan Science And Technology Agency 金属錯体型核酸
WO2007005626A1 (en) * 2005-07-01 2007-01-11 Bioveris Corporation Compositions and methods for detecting, amplifying, and/or isolating nucleic acids
WO2009065181A1 (en) * 2007-11-21 2009-05-28 Apollo Life Sciences Limited Nanostructures suitable for delivery of agents

Also Published As

Publication number Publication date
MX2013001668A (es) 2013-07-22
HUE029521T2 (en) 2017-03-28
KR101606495B1 (ko) 2016-03-28
JP2013536195A (ja) 2013-09-19
CL2013000445A1 (es) 2013-11-22
ES2598556T3 (es) 2017-01-27
CA2806616A1 (en) 2012-02-23
JP5775581B2 (ja) 2015-09-09
ZA201300497B (en) 2013-09-25
EA201300259A1 (ru) 2013-12-30
US8513211B2 (en) 2013-08-20
EA026660B1 (ru) 2017-05-31
SMT201600370B (it) 2016-11-10
BR112013003875B1 (pt) 2021-10-05
US8716259B2 (en) 2014-05-06
AU2011291401A1 (en) 2013-01-10
HRP20161333T1 (hr) 2016-12-02
CN103052405A (zh) 2013-04-17
EP2605794B1 (en) 2016-07-20
RS55245B1 (sr) 2017-02-28
IL224237A (en) 2015-09-24
PL2605794T3 (pl) 2017-01-31
KR20150082685A (ko) 2015-07-15
CR20130069A (es) 2013-09-20
US20130296410A1 (en) 2013-11-07
KR20150039873A (ko) 2015-04-13
US20120046348A1 (en) 2012-02-23
SG187165A1 (en) 2013-02-28
HK1184058A1 (zh) 2014-01-17
PH12013500192B1 (en) 2018-11-23
MX340294B (es) 2016-07-04
CU20130022A7 (es) 2013-04-19
MY160961A (en) 2017-03-31
CA2855690A1 (en) 2012-02-23
KR20130099067A (ko) 2013-09-05
CA2855690C (en) 2015-08-25
PH12013500192A1 (cg-RX-API-DMAC10.html) 2013-03-11
AU2011291401B2 (en) 2014-11-27
WO2012021985A1 (en) 2012-02-23
CA2806616C (en) 2015-08-11
ECSP13012449A (es) 2013-04-30
LT2605794T (lt) 2016-10-25
GT201300040A (es) 2014-09-02
HK1198123A1 (en) 2015-03-13
CN103052405B (zh) 2015-11-25
PT2605794T (pt) 2016-10-25
DOP2013000041A (es) 2017-12-15
DK2605794T3 (en) 2016-10-24
EP2605794A4 (en) 2014-07-02
CO6670525A2 (es) 2013-05-15
BR112013003875A2 (en) 2018-03-13
CY1118207T1 (el) 2017-06-28
CN103768086A (zh) 2014-05-07
EP2605794A1 (en) 2013-06-26
SI2605794T1 (sl) 2017-01-31
CN103768086B (zh) 2015-10-14

Similar Documents

Publication Publication Date Title
IL258908A (en) Bismam thiols as disinfectants for use in agriculture, industry and other uses
MX2013012542A (es) Compuestos de amida y aplicacion farmaceutica para el mismo.
MX361413B (es) Formas cristalinas de un macrólido y usos para las mismas.
SG10201804331TA (en) Oligonucleotide conjugates
EP2605794A4 (en) Oligonucleotide chelate complexes
MY158982A (en) Heterocyclic compound
IL242710B (en) Use of a carrier-oligosaccharide conjugate containing an oligosaccharide attached to a carrier for the production of a drug
AP2010005429A0 (en) The use of solid carrier particles to improve the processability of a pharmaceutical agent.
MX356625B (es) Oligonucleotidos para elaborar un cambio en la secuencia de una molécula de ácido ribonucleico objetivo presente en una célula viva.
PH12013501127A1 (en) Use of sigma ligands in bone cancer pain
PH12012501814A1 (en) Fe(iii) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias
MX359825B (es) Compuesto pirazol y su uso farmaceutico.
PL2531505T3 (pl) Sposób wytwarzania kompleksów 3,7-diaza-bicyklo[3.3.1]nonanu z metalami
IN2014DN06202A (cg-RX-API-DMAC10.html)
MX2012010448A (es) Conjugados de carbohidrato-poli aminoacido-farmaco.
ZA201401710B (en) "new administration regime for n-hydroxy-4-{-3-(n,n-dimethylamethyl)benzofurun-2 ylcarbonylamino]ethoxy}benzaminde"
GEP20146170B (en) Improved process for pharmaceutical compound preparation
MY196288A (en) Bis-imine complex of lanthanides, catalytic system comprising said bis-imine complex and process for the (co) polymerization of conjugated dienes
MY193205A (en) Bis-imine pyridine complex of lanthanides, catalytic system comprising said bis-imine pyridine complex and process for the (co) polymerization of conjugated dienes
WO2007140804A8 (en) A process for the preparation of an oxaliplatin
JO2857B1 (en) Vinyl pipers with modified activity of tumor-resistant TNF
PH12014501664A1 (en) Plant disease control composition
UA38601U (en) 2,2'-dithioxo-4,4'-dioxo-[5,5']-bithiazolidinyl-idene-diyl-3,3'-dibutanoic acid diarylamides having antitumor activity
WO2011161295A3 (es) Uso de compuestos anticalcineurina para el tratamiento de patologías que cursan con neovascularización ocular
MX2011011128A (es) Un producto lacteo bajo en colesterol para uso como un medicamento.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 AUG 2016 BY CPA GLOBAL

Effective date: 20150717

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 AUG 2017 BY NORTON ROSE FULBRIGHT CANADA LLP

Effective date: 20160705

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 AUG 2018 BY DENNEMEYER + CO

Effective date: 20170818

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 AUG 2019 BY DENNEMEYER + CO.

Effective date: 20190122

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 AUG 2020 BY PETRA OLK

Effective date: 20200213

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 AUG 2021 BY CPA GLOBAL

Effective date: 20200806

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 AUG 2022 BY CPAGLOBAL

Effective date: 20210817

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 AUG 2023 BY CPA GLOBAL

Effective date: 20220707

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 AUG 2024 BY CPA GLOBAL

Effective date: 20230811

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 AUG 2025 BY CPA

Effective date: 20250218

LAPS Patent lapsed